Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Loconsole

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Acta Dermato-Venereologica|April 27, 2021
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME StudyAntonio Costanzo, Filomena Russo, Marco Galluzzo, et al.
Dermatology and Therapy|September 24, 2024
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World EvidencePiergiorgio Malagoli, Paolo Dapavo, Paolo Amerio, et al.
Dermatology and Therapy|February 16, 2026
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis)Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 5, 2025
<i>Letter:</i> Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL ADGiuseppe Lauletta, Luca Potestio, Cataldo Patruno, et al.
Journal of Clinical Medicine|May 28, 2022
Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient WellbeingFrancesca Prignano, Alexandra M G Brunasso, Gabriella Fabbrocini, et al.
Dermatology Practical & Conceptual|March 30, 2026
CORONATE: A Novel Questionnaire to Assess the Long-Term Impact of Psoriasis on Patients' LivesStefano Piaserico, Francesca Sampogna, Martina Accorinti, et al.
Dermatology and Therapy|July 3, 2025
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Journal of Clinical Medicine|May 27, 2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus StatementMaria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Journal of Clinical Medicine|January 11, 2024
Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe PsoriasisFrancesca Prignano, Giuseppe Argenziano, Federico Bardazzi, et al.
Clinical and Experimental Dermatology|November 1, 2025
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Luca Potestio, Maria Concetta Fargnoli, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Acta Dermato-Venereologica|April 27, 2021
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME StudyAntonio Costanzo, Filomena Russo, Marco Galluzzo, et al.
Dermatology and Therapy|September 24, 2024
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World EvidencePiergiorgio Malagoli, Paolo Dapavo, Paolo Amerio, et al.
Dermatology and Therapy|February 16, 2026
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis)Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 5, 2025
<i>Letter:</i> Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL ADGiuseppe Lauletta, Luca Potestio, Cataldo Patruno, et al.
Journal of Clinical Medicine|May 28, 2022
Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient WellbeingFrancesca Prignano, Alexandra M G Brunasso, Gabriella Fabbrocini, et al.
Dermatology Practical & Conceptual|March 30, 2026
CORONATE: A Novel Questionnaire to Assess the Long-Term Impact of Psoriasis on Patients' LivesStefano Piaserico, Francesca Sampogna, Martina Accorinti, et al.
Dermatology and Therapy|July 3, 2025
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Journal of Clinical Medicine|May 27, 2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus StatementMaria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Journal of Clinical Medicine|January 11, 2024
Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe PsoriasisFrancesca Prignano, Giuseppe Argenziano, Federico Bardazzi, et al.
Clinical and Experimental Dermatology|November 1, 2025
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Luca Potestio, Maria Concetta Fargnoli, et al.
Pageof 8